Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns: Original scientific article. (2025). ADMET and DMPK, 2956. https://doi.org/10.5599/admet.2956